WCT selected to conduct Ph III NurOwn Trial in ALS

By Melissa Fassbender contact

- Last updated on GMT

Worldwide Clinical Trials is a contract research organization (CRO) with offices in North and South America, Eastern and Western Europe, Russia, and Asia. (Image: iStock/BernardaSv)
Worldwide Clinical Trials is a contract research organization (CRO) with offices in North and South America, Eastern and Western Europe, Russia, and Asia. (Image: iStock/BernardaSv)

Related tags: Contract research organization, Clinical trial

BrainStorm Cell Therapeutics has contracted Worldwide Clinical Trials (WCT) to conduct its planned Phase III study of NurOwn in the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases.

According to New Jersey-based company, a study kick-off meeting is expected later this month.

The company has an exclusive, worldwide licensing agreement with Ramon, Tel Aviv University’s technology transfer company, through which it holds the rights to develop and commercialize the NurOwn technology.

NurOwn previously demonstrated a clinically meaningful benefit of the technology in a randomized, double-blind, placebo-controlled clinical trial conducted in the US.

Subsequently, Brainstorm will conduct a randomized, double-blind, placebo-controlled multi-dose Phase III trial at multiple sites with support from WCT.

Chaim Lebovits, BrainStorm Cell Therapeutics CEO said selecting a contract research organization (CRO) is “a critical step before initiating patient enrollment​” into the company’s Phase III study of NurOwn.

Related news

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 07-Dec-2021 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

Related suppliers

Follow us

Products

View more

Webinars